The U.S. House Appropriations Committee released its report accompanying the FY20 Defense Appropriations Act.

It contains an increase to $30 million annually for the kidney cancer research program.

Led by KidneyCan, a coalition of patients, caregivers and representatives of other patient advocacy organizations all pitched in to advocate for this much needed increase in research for a cure.

The increase still needs House and Senate approval along with the President’s signature to become law. We have a ways to go to the finish line but this is an important step in the process. Historically, figures included in the House bill ultimately become law.

The Kidney Cancer Research (KCRP) within the CDMRP table starts on p. 303: